NEW YORK, June 5 - Genomics stocks jumped Tuesday, tagging along as investors drove up the Nasdaq by 3.6 percent and the Amex Biotechnology Index to a six-month high.

"Because Nasdaq is looking a little better, investors are looking [to be] a little more adventurous," said James Reddoch, an analyst at Banc of America Securities.

Some genomics companies won't be profitable for another four years, he added, but risk-tolerant investors are beginning to appreciate that a few companies "have a huge amount of value that is hard to quantitate."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.